Exploiting tumour biology to develop novel drug delivery strategies for PDT

Medical Laser Application

Volumn 21, Issue 4, 2006, Pages 225-238

  Wojtyk, James T C ^a   Goyan, Rebecca ^a   Gudgin Dickson, Eva ^a   Pottier, Roy ^a  

^a ROYAL MILITARY COLLEGE OF CANADA   (Canada)

Author keywords

Glycoconjugated photosensitizers; Peptide based delivery vectors; Photodynamic therapy; Photoimmunoconjugates; Prodrug therapies; Protease mediated drug delivery; Tumour marker directed therapy

Indexed keywords

BIOLOGICAL MEMBRANES; DRUG THERAPY; ENZYMES; PATIENT TREATMENT; PHOTOSENSITIZERS; TUMORS;

GLYCOCONJUGATED PHOTOSENSITIZERS; PEPTIDE-BASED DELIVERY VECTORS; PHOTOIMMUNOCONJUGATES; PRODRUG THERAPIES; PROTEASE-MEDIATED DRUG DELIVERY; TUMOR-MARKER DIRECTED THERAPY;

PHOTODYNAMIC THERAPY;

AMINOCAMPTHECIN; ANTIGEN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZOPORPHYRIN DERIVATIVE; CELL ENZYME; CELL SURFACE RECEPTOR; CHLORIN E6; CHLOROALUMINUM PHTHALOCYANINE TETRASULFONATE; DOXORUBICIN; FOLATE RECEPTOR; HEMATOPORPHYRIN DERIVATIVE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; INDIUM PORPHYRIN; ISOTHIOCYANIC ACID; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; MATRIX METALLOPROTEINASE; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; PACLITAXEL; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; POLYLYSINE; POLYMER; PRODRUG; PYROPHEOPHORBIDE A; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ARTICLE; CARBOHYDRATE ANALYSIS; CELL SURFACE; CELLULAR DISTRIBUTION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; HUMAN; IMMUNE SYSTEM; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET CELL; TUMOR; TUMOR CELL;

EID: 33750997900     PISSN: 16151615     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mla.2006.07.005     Document Type: Article

References (139)

1. Pachence J.M., and Simon P. Novel methods for site-directed drug delivery. Drug Delivery Technol 3 (2003)
2. Willis R.C. Good things in small packages. Nanotech advances are producing mega-results in drug delivery. Mod Drug Discov 7 (2004) 30-36
3. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., and Kessel D. Photodynamic therapy. J Natl Cancer Inst 90 (1998) 889-905
4. Wilson B.C., and Patterson M.S. The physics of photodynamic therapy. Phys Med Biol 31 (1986) 327-360
5. Niedre M., Patterson M.S., and Wilson B.C. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem Photobiol 75 (2002) 382-391
6. Bisland S.K. Strategies for drug delivery: perspectives in photodynamic therapy. Recent Res Develop Bioconj Chem 2 (2005) 1-43
7. Gudgin-Dickson E.F., Goyan R.L., and Pottier R.H. New directions in photodynamic therapy. Cell Mol Biol 48 8 (2002) 939-954
8. Nyman E.S., and Hynninen P.H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B: Biol 73 (2004) 1-28
9. Kennedy J.C., Marcus S.L., and Pottier R.H. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 14 (1996) 289-304
10. McCaughan Jr. J.S. Photodynamic therapy: a review. Drugs Aging 15 (1999) 49-68
11. Pass H.I. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 85 (1993) 443-456
12. Damle N.K., and Frost P. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 3 (2003) 386-390
13. Kosmas C., Linardou H., and Epenetos A.A. Review: advances in monoclonal antibody tumour targeting. J Drug Target 1 (1993) 81-91
14. Pietersz G.A., and Krauer K. Antibody-targeted drugs for the therapy of cancer. J Drug Target 2 (1994) 183-215
15. Yarmush M.L., Thorpe W.P., Strong L., Rakestraw S.L., Toner M., and Tompkins R.G. Antibody targeted photolysis. Crit Rev Ther Drug Carrier Syst 10 (1993) 197-252
16. Bedel-Cloutour C.H., Mauclaire L., Saux A., and Pereyre M. Syntheses of functionalized indium porphyrins for monoclonal antibody labeling. Bioconj Chem 7 (1996) 617-627
17. Carcenac M., Dorvillius M., Garambois V., Glaussel F., Larroque C., Langlois R., et al. Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br J Cancer 85 (2001) 1787-1793
18. Jiang F.N., Jiang S., Liu D., Richter A., and Levy J.G. Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods 134 (1990) 139-149
19. Mew D., Wat C.K., Towers G.H., and Levy J.G. Photoimmunotherapy: treatment of animal tumours with tumour-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 130 (1983) 1473-1477
20. Pardridge W.M., Buciak J., Yang J., and Wu D. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. J Pharmacol Exp Ther 286 (1998) 548-554
21. Rakestraw S.L., Tompkins R.G., and Yarmush M.L. Antibody-targeted photolysis: in vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier. Proc Natl Acad Sci USA 87 (1990) 4217-4221
22. Hudson R., Carcenac M., Smith K., Madden L., Clarke O.J., Pelegrin A., et al. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br J Cancer 92 (2005) 1442-1449
23. Del Governatore M., Hamblin M.R., Piccinini E.E., Ugolini G., and Hasan T. Targeted photodestruction of human colon cancer cells using charged chlorin e6 immunoconjugates. Br J Cancer 82 (2000) 56-64
24. Hamblin M.R., Del Governatore M., Rizvi I., and Hasan T. Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. Br J Cancer 83 (2000) 1544-1551
25. Oseroff A.R., Ara G., Ohuoha D., Aprille J., Bommer J.C., Yarmush M.L., et al. Strategies for selective cancer photochemotherapy: antibody-targeted and selective carcinoma cell photolysis. Photochem Photobiol 46 (1987) 83-96
26. Jiang F.N., Liu D.J., Neyndorff H., Chester M., Jiang S.Y., and Levy J.G. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J Natl Cancer Inst 83 (1991) 1218-1225
27. Mew D., Lum V., Wat C.K., Towers G.H., Sun C.H., and Walter R.J. Cancer Res 45 (1985) 4380-4386
28. Oseroff A.R., Ohuoha D., Hasan T., Bommer J.C., and Yarmush M.L. Antibody-targeted photolysis: selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci USA 83 (1986) 8744-8748
29. Trail P.A., King H.D., and Dubowchik G.M. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 52 (2003) 328-337
30. Carcenac M., Larroque C., Langlois R., van Lier J.E., Artus J.C., and Pelegrin A. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates. Photochem Photobiol 70 (1999) 930-936
31. Savellano M.D., Pogue B.W., Hoopes P.J., Vitetta E.S., and Paulsen K.D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide - a immunoconjugates. Cancer Res 65 (2005) 6371-6379
32. Akhlynina T.V., Jans D.A., Rosenkranz A.A., Statsyuk N.V., Balashova I.Y., Toth G., et al. Nuclear targeting of chlorin e6 enhances its photosensitizing activity. J Biol Chem 272 (1997) 20328-20331
33. Jiang F.N., Richter A.M., Jain A.K., Levy J.G., and Smits C. Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A549-tumour-bearing nude mice. Biotechnol Ther 4 (1993) 43-61
34. Hamblin M.R. Cationic photoimmunoconjugates between monoclonal antibodies and hematoporphyrin: selective photodestruction of ovarian cancer cells. Appl Opt 37 (1998) 7184-7192
35. Krinick N.L. Soluble polymers as targetable drug carriers. In: Juliano R.L. (Ed). Targeted drug delivery (1991), Springer, Berlin 105-166
36. Illum L., and Jones P.D. Attachment of monoclonal antibodies to microspheres. Methods Enzymol 112 (1985) 67-84
37. Cobb P.W., and LeMaistre C.F. Therapeutic use of immunotoxins. Semin Hematol 29 (1992) 6-13
38. Oldham R.K. Monoclonal antibodies in cancer therapy. J Clin Oncol 1 (1983) 582-590
39. Moolten F.L., Schreiber B.M., and Zajdel S.H. Antibodies conjugated to potent cytotoxins as specific antitumour agents. Immunol Rev 62 (1982) 47-73
40. Jain R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumours. Cancer Res 50 (1990) 814-819
41. Jain R.K. Delivery of molecular and cellular medicine to solid tumours. J Control Release 53 (1998) 49-67
42. Eccles S.A. Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?. Breast Cancer Res 3 (2001) 86-90
43. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23 (2005) 1126-1136
44. Astier A. New drug formulations for cancer therapy. Ann Pharm Fr 64 (2006) 23-35
45. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99 (2002) 157-166
46. Connors T. Enzyme-prodrug strategies for cancer therapy. In: Melton R.G., and Knox R.J. (Eds) (1999), Kluwer Academic/Plenum Press, New York
47. Han H.K., and Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharm Sci 2 (2000) E6
48. Xu G., and McLeod H.L. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res 7 (2001) 3314-3324
49. Bottiroli G., Croce A.C., Balzarini P., Locatelli D., Baglioni P., Lo Nostro P., et al. Enzyme-assisted cell photosensitization: a proposal for an efficient approach to tumour therapy and diagnosis. The rose bengal fluorogenic substrate. Photochem Photobiol 66 (1997) 374-383
50. Silva A.T., Chung M.C., Castro L.F., Guido R.V., and Ferreira E.I. Advances in prodrug design. Mini Rev Med Chem 5 (2005) 893-914
51. Stefflova K., Chen J., Marotta D., Li H., and Zheng G. Photodynamic therapy agent with a built-in apoptosis sensor for evaluating its own therapeutic outcome in situ. J Med Chem 49 (2006) 3850-3856
52. Chen J., Stefflova K., Niedre M.J., Wilson B.C., Chance B., Glickson J.D., et al. Protease-triggered photosensitizing beacon based on singlet oxygen quenching and activation. J Am Chem Soc 126 (2004) 11450-11451
53. Kennedy JC, Ringuet M, Pottier RH. Protease mediated drug delivery system. US Patent 5618790, 1997.
54. Nagase H., and Woessner Jr. J.F. Matrix metalloproteinases. J Biol Chem 274 (1999) 21491-21494
55. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., et al. Multifunctional potential of the plasminogen activation system in tumour invasion and metastasis. Int J Oncol 13 (1998) 893-906
56. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., et al. A new approach for the treatment of malignant melanoma: enhanced antitumour efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 63 (2003) 4062-4066
57. Dubois V., Dasnois L., Lebtahi K., Collot F., Heylen N., Havaux N., et al. CPI-0004Na, a new extracellularly tumour-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumour cell selectivity. Cancer Res 62 (2002) 2327-2331
58. Chourasia M.K., and Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 6 (2003) 33-66
59. Gao S.Q., Lu Z.R., Petri B., Kopeckova P., and Kopecek J. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release 110 (2006) 323-331
60. Burke M.D., Park J.O., Srinivasarao M., and Khan S.A. A novel enzymatic technique for limiting drug mobility in a hydrogel matrix. J Control Release 104 (2005) 141-153
61. Duncan R. N-(2-hydroxypropyl)methacrylamide copolymer conjugates. In: Kwon G. (Ed). Polymeric drug delivery systems vol. 148 (2005), Marcel Dekker, New York 1-92
62. Shaffer S.A. Proteolysis of xyotaxe by lysosomal cathepsin B; metabolic profiling in tumour cells using LC-MS. Eur J Cancer 38 (2002) S129
63. Ulbrich K., and Subr V. Polymeric anticancer drugs with pH-controlled, activation. Adv Drug Deliv Rev 56 (2004) 1023-1050
64. Duncan R., Rejmanova P., Kopecek J., and Lloyd J.B. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim Biophys Acta 678 (1981) 143-150
65. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., et al. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat. Cancer Chemother Pharmacol 29 (1991) 105-111
66. Minko T., Kopeckova P., Pozharov V., and Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54 (1998) 223-233
67. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2 (2002) 750-763
68. Bange J., Zwick E., and Ullrich A. Molecular targets for breast cancer therapy and prevention Nature Medicine 7 (2001) 548-552
69. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 (2005) 145-160
70. Lombardi P., Norata G., Maggi F.M., Canti G., Franco P., Nicolin A., et al. Assimilation of LDL by experimental tumours in mice. Biochim Biophys Acta 1003 (1989) 301-306
71. West C.M., West D.C., and Moore J.V. Low-density lipoprotein uptake and the sensitivity to photodynamic treatment of cultured endothelial cells. Int J Radiat Biol 60 (1991) 25-28
72. Kongshaug M. Distribution of tetrayrrole potosensitiers among human plasma proteins. Int J Biochem 34 (1992) 1239-1265
73. Jori G., Beltramini E., Reddi B., Salvato A., Pagnan L., Ziron L., et al. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. Cancer Lett 24 (1987) 291-297
74. Jori G. Factors controlling the selectivity and efficiency of tumour damage of photodynamic therapy. Lasers Med Sci 5 (1990) 115-120
75. Bachor R., Shea C.R., Gillies R., and Hasan T. Photosensitized destruction of human bladder carcinoma cells treated with chlorin e6-conjugated microspheres. Proc Natl Acad Sci USA 88 (1991) 1580-1584
76. Schmidt-Erfurth U., Diddens H., Birngruber R., and Hasan T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer 75 (1997) 54-61
77. Demidova T.N., and Hamblin M.R. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol 17 (2004) 117-126
78. Liu Q., and Hamblin M.R. Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state. Int J Immunopathol Pharmacol 18 (2005) 391-402
79. Thierry A.R., Vige D., Coughlin S.S., Belli J.A., Dritschilo A., and Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. Faseb J 7 (1993) 572-579
80. Lutwyche P., Cordeiro C., Wiseman D.J., St-Louis M., Uh M., Hope M.J., et al. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 42 (1998) 2511-2520
81. Lamparski H., Liman U., Barry J.A., Frankel D.A., Ramaswami V., Brown M.F., et al. Photoinduced destabilization of liposomes. Biochemistry 31 (1992) 685-694
82. Bennett D.E., Lamparski H., and O'Brien D.F. Photosensitive liposomes. J Liposome Res 4 (1994) 331-348
83. Ono N., Bougauchi M., and Maruyama K. Water-soluble porphyrins with four sugar molecules. Tet Lett 33 (1992) 1629-1632
84. Sol V., Blais J.C., Bolbach G., Carré V., Granet R., Guilloton M., et al. Toward glycosylated peptidic porphyrins: a new strategy for PDT?. Tet Lett 38 (1997) 6391-6394
85. Maillard P., Hery C., and Momenteau M. Synthesis, characterization and phototoxicity of a glycoconjugated meso-monoarylbenzochlorin. Tet Lett 38 (1997) 3731-3734
86. Yang R.Y., and Liu F.T. Galectins in cell growth and apoptosis. Cell Mol Life Sci 60 (2003) 267-276
87. Brewer C.F., Miceli M.C., and Baum L.G. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol 12 (2002) 616-623
88. Rabinovich G.A., Baum L.G., Tinari N., Paganelli R., Natoli C., Liu F.T., et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. Trends Immunol 23 (2002) 313-320
89. Riss D., Jin L., Qian X., Bayliss J., Scheithauer B.W., Young Jr. W.F., et al. Differential expression of galectin-3 in pituitary tumours. Cancer Res 63 (2003) 2251-2255
90. Rini J.M. Lectin structure. Annu Rev Biophys Biomol Struct 24 (1995) 551-577
91. Fujimoto K., Miyata T., and Aoyama Y. Saccharide-directed cell recognotion and molecular delivery using macrocylic saccharide clusters: masking of hydrophobicity to nehance the saccharide specificity. J Am Chem Soc 122 (2000) 3558-3559
92. Chen X., Hui L., Foster D.A., and Drain C.M. Efficient synthesis and photodynamic activity of porphyrin-saccharide conjugates: targeting and incapacitating cancer cells. Biochemistry 43 (2004) 10918-10929
93. Li G., Pandey S.K., Graham A., Dobhal M.P., Mehta R., Chen Y., et al. Functionalization of OEP-based benzochlorins to develop carbohydrate-conjugated photosensitizers. Attempt to target beta-galactoside-recognized proteins. J Org Chem 69 (2004) 158-172
94. Laville I., Pigaglio S., Blais J.C., Doz F., Loock B., Maillard P., et al. Photodynamic efficiency of diethylene clycol-linked glycoconjugated porphyrins in human retinoblastoma cells. J Med Chem 49 (2006) 2558-2567
95. Garin-Chesa P., Campbell I., Saigo P.E., Lewis Jr. J.L., Old L.J., and Rettig W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 142 (1993) 557-567
96. Sudimack J., and Lee R.J. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41 (2000) 147-162
97. Reddy J.A., and Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 15 (1998) 587-627
98. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 10 (1999) 289-298
99. Lee R.J., and Low P.S. Folate-mediated tumour cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233 (1995) 134-144
100. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., and Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6 (2000) 1949-1957
101. Pan X.Q., Zheng X., Shi G., Wang H., Ratnam M., and Lee R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100 (2002) 594-602
102. Guo W., Lee T., Sudimack J.J., and Lee R.J. Receptor-specific Targeted liposomal drug delivery to solid tumour delivery of liposomes via folate-PEG-chol. J Liposome Res 10 (2000) 179-195
103. Turk M.J., Breur G.J., Widmer W.R., Paulos C.M., Xu L.C., Grote L.A., et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 46 (2002) 1947-1955
104. Pan X.Q., Wang H., and Lee R.J. Boron delivery to a murine lung carcinoma using folate receptor-targeted liposomes. Anticancer Res 22 (2002) 1629-1633
105. Pan X.Q., Wang H., and Lee R.J. Antitumour activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 20 (2003) 417-422
106. Rui Y., Wang S., Low P.S., and Thompson D.H. Diplasmenylcholine-folate liposomes: an efficient vehicle for intracellular drug delivery. J Am Chem Soc 120 (1998) 11213-11218
107. Qualls M.M., and Thompson D.H. Chloroaluminum phthalocyanine tetrasulfonate delivered via acid-labile diplasmenylcholine-folate liposomes: intracellular localization and synergistic phototoxicity. Int J Cancer 93 (2001) 384-392
108. Reubi J.C. In vitro identification of vasoactive intestinal peptide receptors in human tumours: implications for tumour imaging. J Nucl Med 36 (1995) 1846-1853
109. Reubi J.C. In vitro identification of VIP receptors in human tumours: potential clinical implications. Ann N Y Acad Sci 805 (1996) 753-759
110. Reubi J.C., Laderach U., Waser B., Gebbers J.O., Robberecht P., and Laissue J.A. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumours and their tissues of origin. Cancer Res 60 (2000) 3105-3112
111. Sethi V., Onyuksel H., and Rubinstein L. Liposomal vasoactive intestinal peptide. Methods Enzymol 391 (2005) 377-395
112. Dagar S., Krishnadas A., Rubinstein I., Blend M.J., and Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 91 (2003) 123-133
113. Bisland S.K., Singh D., and Gariepy J. Potentiation of chlorin e6 photodynamic activity in vitro with peptide-based intracellular vehicles. Bioconjug Chem 10 (1999) 982-992
114. Tijerina M., Kopeckova P., and Kopecek J. Mechanisms of cytotoxicity in human ovarian carcinoma cells exposed to free Mce6 or HPMA copolymer-Mce6 conjugates. Photochem Photobiol 77 (2003) 645-652
115. Tijerina M., Kopeckova P., and Kopecek J. Correlation of subcellular compartmentalization of HPMA copolymer-Mce6 conjugates with chemotherapeutic activity in human ovarian carcinoma cells. Pharm Res 20 (2003) 728-737
116. Akhlynina T.V., Rosenkranz A.A., Jans D.A., Gulak P.V., Serebryakova N.V., and Sobolev A.S. The use of internalizable derivatives of chlorin E6 for increasing its photosensitizing activity. Photochem Photobiol 58 (1993) 45-48
117. Akhlynina T.V., Jans D.A., Statsyuk N.V., Balashova I.Y., Toth G., Pavo I., et al. Adenoviruses synergize with nuclear localization signals to enhance nuclear delivery and photodynamic action of internalizable conjugates containing chlorin e6. Int J Cancer 81 (1999) 734-740
118. Chaloin L., Bigey P., Loup C., Marin M., Galeotti N., Piechaczyk M., et al. Improvement of porphyrin cellular delivery and activity by conjugation to a carrier peptide. Bioconjug Chem 12 (2001) 691-700
119. Sibrian-Vazquez M., Jensen T.J., Fronczek F.R., Hammer R.P., and Vicente M.G. Synthesis and characterization of positively charged porphyrin-peptide conjugates. Bioconjug Chem 16 (2005) 852-863
120. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278 (2003) 585-590
121. Vernon D, Walker I, Brown S. Synthesis and in vitro testing of photosensitiser-peptide conjugates for use in photodynamic therapy. In: Eleventh Congress of the European Society for Photobiology, Aix-Les-Bains, France, 2005. p. 63.
122. Sibrian-Vazquez M., Jensen T.J., Hammer R.P., and Vicente M.G. Peptide-mediated cell transport of water soluble porphyrin conjugates. J Med Chem 49 (2006) 1364-1372
123. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2 (2003) 214-221
124. Pasut G. Protein, peptide and non-peptide drug PEGylation for therapeutic application. Expert Opin Therap Patents 14 (2004) 859-894
125. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 (2003) 347-360
126. Soukos N.S., Hamblin M.R., and Hasan T. The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates. Photochem Photobiol 65 (1997) 723-729
127. Gijsens A., Missiaen L., Merlevede W., and de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res 60 (2000) 2197-2202
128. Davis N., Liu D., Jain A.K., Jiang S.Y., Jiang F., Richter A., et al. Modified polyvinyl alcohol-benzoporphyrin derivative conjugates as phototoxic agents. Photochem Photobiol 57 (1993) 641-647
129. Kopecek J., Kopeckova P., Minko T., and Lu Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 50 (2000) 61-81
130. Shiah J.J., Sun Y., Peterson C.M., and Kopecek J. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 61 (1999) 145-157
131. Nishiyama N., Stapert H.R., Zhang G.D., Takasu D., Jiang D.L., Nagano T., et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjug Chem 14 (2003) 58-66
132. Zhang G.D., Harada A., Nishiyama N., Jiang D.L., Koyama H., Aida T., et al. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release 93 (2003) 141-150
133. Maeda H., Fang J., Inutsuka T., and Kitamoto Y. Vascular permeability enhancement in solid tumour: various factors, mechanisms involved and its implications. Int Immunopharmacol 3 (2003) 319-328
134. Kleszczynska H., Bonarska D., Luczynski J., and Witek S. The interaction of some lysosomotropic substances with erythrocyte membrane cell. Biol Mol Lett 6 (2001)
135. De Duve C. Lysosomotropic agents. Biochem Pharmacol 23 (1974) 2495-2531
136. Vicent M.J., and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 24 (2006) 39-47
137. Kovar M., Strohalm J., Etrych T., Ulbrich K., and Rihova B. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumour effect. Bioconjug Chem 13 (2002) 206-215
138. Dubowchik G.M., Radia S., Mastalerz H., Walker M.A., Firestone R.A., Dalton King H., et al. Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages. Bioorg Med Chem Lett 12 (2002) 1529-1532
139. Dubowchik G.M., Firestone R.A., Padilla L., Willner D., Hofstead S.J., Mosure K., et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 13 (2002) 855-869